多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床分析

Combination of docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer

目的:观察多西紫杉醇(艾素)联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应。方法:对病理学或细胞学证实的36例晚期非小细胞肺癌患者给予艾素联合顺铂治疗。采用分次疗法,艾素37.5mg/m2/次,静滴,第1、8天二次给药;顺铂25mg/m2/次静滴,第2-5天。每21天为1周期,每例患者均接受2周期治疗或以上。结果:全组36例中完全缓解1例,部分缓解14例,稳定14例,进展7例,总有效率41.7%。中位生存期8.6个月,1年生存率为38.9%。临床最常见的不良反应为骨髓抑制,Ⅲ、Ⅳ度白细胞下降率为27.8%,其余无严重不良反应。结论:多西紫杉醇联合顺铂治疗晚期非小细胞肺癌疗效较好,不良反应较轻,采用分次疗法,病人耐受性较好,尤对老年晚期患者更加适宜。

Objective：To evaluate the effects and toxicities of the combination of docetaxel and cisplatin in the treatment of patients with advanced non - small cell lung cancer （ NSCLC ）. Methods： Thirty - six patients with advanced NSCLC diagnosed by pathologic or cytologic examination were enrolled into the study. The patients received docetaxel 37.5mg/ （m^2· d） on d1,8 ,and cisplatin 25 mg/m^2 on d2-5 of 21 - day cycle. Each patient should at least complete two cycles. Results： Out of 36 evaluable patients, 1 achieved complete response, 14 achieved partial response, 14 had stable disease , and 7 were progressive with an overall response rate of 41.7%. The median survival time was 8.6 months. The survival rate of 1 - year was 38.9%. The main toxicities were leukopenia （27.8% in grade Ⅲ ＋ Ⅳ ）. Conclusion： Docetaxel combined with eisplatin is effective and active. This divided scheme make its toxicity slight and well tolerated especially for the old and advanced patients.